These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33151020)

  • 1. Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.
    Ross J; Jiamsakul A; Kumarasamy N; Azwa I; Merati TP; Do CD; Lee MP; Ly PS; Yunihastuti E; Nguyen KV; Ditangco R; Ng OT; Choi JY; Oka S; Sohn AH; Law M
    HIV Med; 2021 Mar; 22(3):201-211. PubMed ID: 33151020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
    Jiamsakul A; Sungkanuparph S; Law M; Kantor R; Praparattanapan J; Li PC; Phanuphak P; Merati T; Ratanasuwan W; Lee CK; Ditangco R; Mustafa M; Singtoroj T; Kiertiburanakul S;
    J Int AIDS Soc; 2014; 17(1):19053. PubMed ID: 25141905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia.
    Teeraananchai S; Law M; Boettiger D; Mata N; Gupte N; Chan YL; Pham TN; Chaiwarith R; Ly PS; Chan YJ; Kiertiburanakul S; Khusuwan S; Zhang F; Yunihastuti E; Kumarasamy N; Pujari S; Azwa I; Somia IKA; Tanuma J; Ditangco R; Choi JY; Ng OT; Do CD; Gani Y; Ross J; Jiamsakul A;
    J Int AIDS Soc; 2022 Aug; 25(8):e25989. PubMed ID: 36028921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.
    Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG
    Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.
    Salou M; Dagnra AY; Butel C; Vidal N; Serrano L; Takassi E; Konou AA; Houndenou S; Dapam N; Singo-Tokofaï A; Pitche P; Atakouma Y; Prince-David M; Delaporte E; Peeters M
    J Int AIDS Soc; 2016; 19(1):20683. PubMed ID: 27125320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
    HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.
    Omooja J; Nannyonjo M; Sanyu G; Nabirye SE; Nassolo F; Lunkuse S; Kapaata A; Segujja F; Kateete DP; Ssebaggala E; Bbosa N; Aling E; Nsubuga RN; Kaleebu P; Ssemwanga D
    J Antimicrob Chemother; 2019 Oct; 74(10):3021-3029. PubMed ID: 31257432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
    HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
    Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
    Geretti AM; Abdullahi A; Mafotsing Fopoussi O; Bonnett L; Defo VF; Moudourou S; Fokam J; Kouanfack C; Torimiro J
    J Antimicrob Chemother; 2019 Oct; 74(10):3011-3015. PubMed ID: 31299067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
    Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of switch to paediatric second-line antiretroviral therapy after first-line failure in Cameroon.
    Njom-Nlend AE; Efouba N; Brunelle Sandie A; Fokam J
    Trop Med Int Health; 2021 Aug; 26(8):927-935. PubMed ID: 33905593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes and HIV drug resistance of patients switching to second-line regimens after long-term first-line antiretroviral therapy: An observational cohort study.
    Cao P; Su B; Wu J; Wang Z; Yan J; Song C; Ruan Y; Xing H; Shao Y; Liao L
    Medicine (Baltimore); 2018 Jul; 97(28):e11463. PubMed ID: 29995803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China.
    Leng X; Liang S; Ma Y; Dong Y; Kan W; Goan D; Hsi JH; Liao L; Wang J; He C; Zhang H; Xing H; Ruan Y; Shao Y
    BMJ Open; 2014 Oct; 4(10):e005886. PubMed ID: 25319999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.
    Zheng Y; Hughes MD; Lockman S; Benson CA; Hosseinipour MC; Campbell TB; Gulick RM; Daar ES; Sax PE; Riddler SA; Haubrich R; Salata RA; Currier JS
    Clin Infect Dis; 2014 Sep; 59(6):888-96. PubMed ID: 24842909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.